One-Year Outcomes of CGuard Double Mesh Stent in Carotid Artery Disease: A Systematic Review and Meta-Analysis

• Published in: Medicina (Kaunas, Lithuania) Lithuania), 2024-02, Vol.60 (2), p.286
• Main Authors: Tigkiropoulos, Konstantinos, Nikas, Spyridon, Ampatzis-Papadopoulos, Manolis, Sidiropoulou, Katerina, Stavridis, Kyriakos, Karamanos, Dimitrios, Lazaridis, Ioannis, Saratzis, Nikolaos
• Format: Article
• Language: English
• Subjects: Carotid arteries; carotid artery disease; Carotid Artery Diseases - complications; carotid artery stenting; Carotid Stenosis - complications; Carotid Stenosis - surgery; CGuard; Clinical trials; Constriction, Pathologic; Content analysis; Coronary Restenosis - complications; Demographics; dual layer mesh stents; Humans; Intervention; Meta-analysis; Mortality; Prospective Studies; Risk Factors; Software; Statistical analysis; Stent (Surgery); Stents; Stents - adverse effects; Stroke; Stroke - complications; Stroke - etiology; Surgical Mesh - adverse effects; Systematic review; systematic review and meta-analysis; Treatment Outcome; Vein & artery diseases
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina60020286

: Prospective single and multicenter studies have shown improved outcomes of patients who underwent carotid artery stenting with the novel CGuard dual-layer mesh stent at 1 year. : The aim of this study is to conduct a systematic review and meta-analysis of all published studies to assess 1-year efficacy and outcomes of CGuard in patients with carotid stenting. Methods: A systematic search was performed. All studies enrolling at least 20 patients were included in our analysis. The primary endpoints were death (all-cause, cardiovascular and ipsilateral stroke-related death) and stroke rate at 1 year. The secondary endpoint was in-stent restenosis at 1 year. : The final analysis included 1709 patients. The one-year all-cause mortality rate was 2.97% (39/1699, 95% CI: 1.26-6.86%, I = 67%, t = 0.3442, < 0.01), cardiovascular-related death was 0.92% (10/1616, 95% CI: 0.35-2.39%, I = 34%, t = 0.2302, = 0.18), and ipsilateral stroke-related death was 0.3% (1/1649, 95% CI: 0.1-0.87%, I = 0%, t = 0, = 0.69). The one-year ipsilateral stroke rate was 1.21% (16/1649, 95% CI: 0.58-2.5%, I = 28%, t = 0.1433, = 0.23), transient ischemic attacks (TIAs) rate was 1.78% (19/1149, 95% CI: 1.11-2.84%, I = 0%, t = 0, = 0.69), and total composite 1-year stroke/TIA rate was 2.97% (32/1149, 95% CI: 1.84-4.77%, I = 0%, t = 0, = 0.41). The in-stent restenosis rate at 1 year was 1.06% (13/1653, 95% CI: 0.48-2.34%, I = 28%, t = 0.2308, = 0.22). : This meta-analysis shows that CAS with CGuard is safe with minimal neurological adverse events and in-stent restenosis rate at 1 year.